1-5 of 5
Bruce Silver
Close
Sort by
Journal Articles

Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency

Rachael F. Grace, MD, D. Mark Layton, MB, FRCP, Frédéric Galactéros, MDPhD, Christian Rose, MD, Wilma Barcellini, MD, D. Holmes Morton, MD, Eduard J. Van Beers, MD, Hassan M. Yaish, MD, Yaddanapudi Ravindranath, MBBS, Kevin H.M. Kuo, MD MSc, FRCPC, Sujit Sheth, MD, Janet L. Kwiatkowski, MD, Bruce Silver, MD, Charles Kung, Marvin Cohen, Hua Yang, Penelope A. Kosinski, MS, Lei Hua, Ann Barbier, Bertil Glader, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2194.
https://doi.org/10.1182/blood.V130.Suppl_1.2194.2194
Published: 2017
Journal Articles

Population Pharmacokinetics and Pharmacodynamics of AG-348 in Healthy Human Volunteers Guide Dose Selection for the Treatment of Pyruvate Kinase Deficiency

Kha Le, PhD, Marvin Cohen, Yue Chen, Hyeryun Kim, Bruce Silver, Sam Agresta, MD, Elizabeth Merica, Charles Kung, Penelope Kosinski, Lee Silverman, Scott Biller, Hua Yang, PhD
Journal: Blood
Blood (2015) 126 (23): 3336.
https://doi.org/10.1182/blood.V126.23.3336.3336
Published: 2015
Journal Articles

DRIVE PK: A Phase 2 Trial of AG-348 in Patients with Pyruvate Kinase Deficiency

Ann Barbier, Bruce Silver, Elizabeth Merica, Marvin Cohen, Charles Kung, Hua Yang, PhD, Rachael F. Grace, MD, Bertil Glader, MD PhD, Sam Agresta, MD
Journal: Blood
Blood (2015) 126 (23): 4548.
https://doi.org/10.1182/blood.V126.23.4548.4548
Published: 2015
Journal Articles

Phase I Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects

Hua Yang, Elizabeth Merica, Yue Chen, Marvin Cohen, Ronald Goldwater, Collin Hill, Hyeryun Kim, Penelope Kosinski, Charles Kung, Bruce Silver, Luke Utley, Sam Agresta
Journal: Blood
Blood (2014) 124 (21): 4007.
https://doi.org/10.1182/blood.V124.21.4007.4007
Published: 2014
Journal Articles

A Phase 1 Trial of Fluphenazine HCl (Fz), a Serotonin Antagonist, in Relapsed and Refractory Multiple Myeloma

Edward A. Stadtmauer, MD, David Siegel, MD, PhD, Dan T Vogl, MD, MS, James Stinnett, MD, Geetha Narayanan, MD, P.P. Bapsy, MD, Trivadi Ganesan, MBBS, MD, MNAMS, FRCP, MA, PhD, Minish Jain, MD, Sripada V.S.S Prasad, MD, DMs, Douglas S McNair, MD, PhD, Linda DeYoung, PhD, Alice Lane, Bruce Silver, MD
Journal: Blood
Blood (2008) 112 (11): 5188.
https://doi.org/10.1182/blood.V112.11.5188.5188
Published: 2008